Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: A preliminary study

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 80, Issue 1, 1998, Pages 49-54

  Riyazi, Naghmeh ^a   Leeda, Michal ^a   De Vries, Johanna I P ^a   Huijgens, Peter C ^b   Van Geijn, Herman P ^a   Dekker, Gustaaf A ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticardiolipin antibodies; Heparin; Thrombophilia; Uteroplacental insufficiency

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTEIN C; PROTEIN S;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PLACENTA INSUFFICIENCY; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOPHILIA;

EID: 0032450128     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00083-9     Document Type: Article

References (25)

1. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 99:1992;547-553.
2. Dekker G.A., de Vries J.I.P., Doelitzsch P.M., Huijgens P.C., von Bolmberg B.M.E., Jakobs C.et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol. 173:1995;1042-1048.
3. Sibai B.M., Mercer B., Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long term prognosis. Am J Obstet Gynecol. 165:1991;1408-1412.
4. Sullivan C.A., Magann E.F., Perry K.G. Jr., Roberts W.E., Blake P.G., Martin J.N. Jr. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol. 171:1994;940-943.
5. CLASP Collaborative Group. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994;343:619-629.
6. Dekker G.A., van Geijn H.P. Endothelial dysfunction in preeclampsia, part I: primary prevention; therapeutic perspectives. J Perinat Med. 21:1996;99-117.
7. Dekker G.A., van Geijn H.P. Endothelial dysfunction in preeclampsia, part II: reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. J Perinat Med. 24:1996;119-139.
8. Harris E.N. The second international anti-cardiolipin standardization workshop/the Kingston antiphospholipid antibody study (KAPS) group. Am J Clin Pathol. 94:1990;476-484.
9. Kloosterman G.J. The significance of prenatal care. Int J Gynaecol Obstet. 8:1970;895-912.
10. Tait R.C., Walker I.D., Islam S.I.A.M.et al. Protein S deficiency in healthy blood donors [Abstract]. Br J Haematol. 86(Suppl 1):1994;P118.
11. Koster T., Rosendaal F.R., de Ronde H., Briët E.et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis: Leiden Thrombophilia Study. Blood. 85:1995;2756-2761.
12. Koster T., Rosendaal F.R., de Ronde H., Briët E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 342:1993;1503-1506.
13. Miletich J., Sherman L., Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. New Engl J Med. 317:1987;991-996.
14. Tait R.C., Isobel D., Walker J., Perry D.J., Islam S.I.A.M., Daly M.E., McCall F., Conkie J.A., Carrrell R.W. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 87:1994;106-112.
15. Pattison N.S., Birdsall M.A., Chamley L.W., Lubbe W.F. Recurrent fetal loss and the antiphospholipid syndrome. Recent Adv Obstet Gynaecol. 18:1994;23-50.
16. Cowchock S. The role of antiphospholipid antibodies in obstetric medicine. Curr Obstet Med. 1:1991;229-247.
17. Bom van der J.G., Bots M.L., Haverkate F.et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 125(4):1996;265-269.
18. van Pampus M.G., Wolf H., Buller H.R., Huygens P.C., Jacobs C.H.J.M., Dekker G.A. Underlying disorders associated with severe preeclampsia and HELLP syndrome [Abstract]. Am J Obstet Gynecol. 176(suppl 58):1997;S26.
19. Dulitzki M., Pauzner R., Langevitz P., Pras M., Many A., Schiff M. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. J Obstet Gynecol. 87:1996;380-383.
20. Omri A., Delaloye J.F., Anderson H., Bachmann F. LMW heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost. 61:1989;55-56.
21. Saivan S., Giroux M., Dumas J.C., Faure F., Rekik L., Grandjean H.et al. Placental transfer of glycosaminoglycans in the human perfused placental cotyledon model. Eur J Obstet Gynecol Reprod Biol. 42:1991;221-225.
22. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J. 314:1997;253-257.
23. Sturridge F., De Swiet M., Letsky E. The use of low molecular weight heparin for thromboprophylaxis in pregnancy. Br J Obstet Gynaecol. 101:1994;69-71.
24. Sowers M, Corton G, Shapiro B, Jannausch M, Crutchfield M, Smith M. et al. Changes in bone density with lactation. J Am Med Assoc 1993;269:3130:3135.
25. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing, thromboprophylaxis with heparin. Am J Obstet Gynecol. 168:1993;1265-1270.